Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice

Cardiovascular Drugs and Therapy

Volumn 28, Issue 6, 2014, Pages 493-500

  Salloum, Fadi N ^a   Chau, Vinh Q ^a   Hoke, Nicholas N ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cardiomyopathy; Infarct size; LV function; Phosphodiesterase 5 inhibitors

Indexed keywords

TADALAFIL; CARBOLINE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ACUTE HEART FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; EXPERIMENTAL MYOCARDIAL INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; ISCHEMIC CARDIOMYOPATHY; LUNG EDEMA; MALE; MOUSE; NICK END LABELING; NONHUMAN; TREATMENT DURATION; ANIMAL; CARDIOMEGALY; CARDIOMYOPATHIES; CORONARY BLOOD VESSEL; DIET THERAPY; DRUG EFFECTS; HEART FAILURE; INSTITUTE FOR CANCER RESEARCH MOUSE; MYOCARDIAL INFARCTION; PULMONARY EDEMA;

ANIMALS; APOPTOSIS; CARBOLINES; CARDIOMEGALY; CARDIOMYOPATHIES; CORONARY VESSELS; HEART FAILURE; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; PULMONARY EDEMA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84915803910     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6559-0     Document Type: Article

References (35)

1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–82.
2. Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol. 2012;59:1921–7.
3. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol Heart Circ Physiol. 2002;283:H1263–9.
4. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, et al. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol. 2007;42:453–8.
5. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294:H1398–406.
6. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC. Mitigation of the progression of the progression of heart failure with sildenafil involves the inhibition of RhoA/Rho-Kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300:H2272–9.
7. Das A, Smolenski A, Lohmann SM, Kukreja RC. Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J Biol Chem. 2006;281:38644–52.
8. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res. 2005;57:22–7.
9. Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, Ockaili RA, et al. Phosphodiesterase-5 Inhibitor, Tadalafil, Protects against Myocardial Ischemia/Reperfusion through Protein-Kinase G Dependent Generation of Hydrogen Sulfide. Circulation. 2009;120:S31–6.
10. Varma A, Das A, Hoke NN, Durrant DE, Salloum FN, Kukreja RC. Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic Mice. PLoS ONE. 2012;7:e45243.
11. Koka S, Das A, Salloum FN, Kukreja RC. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic Biol Med. 2013;60:80–8.
12. Daugan A, Grondin P, Ruault C, de AC LMG, Coste H, Kirilovsky J, et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor: 1:5,6,11,11a-tetrahydro-1H-imidazo[1’,5’:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J Med Chem. 2003;46:4525–32.
13. Frey MK, Lang I. Tadalafil for the treatment of pulmonary hypertension. Expert Opin Pharmacother. 2012;13:747–55.
14. Nagy O, Hajnal A, Parratt JR, Vegh A. Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol. 2004;141:549–51.
15. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor, sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling. J Biol Chem. 2005;280:12944–55.
16. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. 2001;15:1718–26.
17. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res. 2003;92:595–7.
18. Li Q, Guo Y, Xuan YT, Lowenstein CJ, Stevenson SC, Prabhu SD, et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res. 2003;92:741–8.
19. Toldo S, Das A, Mezzaroma E, Chau VQ, Marchetti C, Durrant D, et al. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet. 2014;7:311–20.
20. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137–44.
21. Westermann D, Becher PM, Lindner D, Savvatis K, Xia Y, Fröhlich M, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107:308.
22. Munjal C, Opoka AM, Osinska H, James JF, Bressan GM, Hinton RB. TGF-β mediates early angiogenesis and latent fibrosis in an Emilin1-deficient mouse model of aortic valve disease. Dis Model Mech. 2014;7:987–96.
23. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119:408–16.
24. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8–17.
25. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44:2339–48.
26. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007;115:59–66.
27. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation. 2012;125:2323–33.
28. Redfield MM, Borlaug BA, Lewis GD, Mohammed SF, Semigran MJ, Lewinter MM, et al. PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. Circ. Heart Fail. 2012;5:653–9.
29. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, et al. RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–77.
30. Wirostko BM, Tressler C, Hwang LJ, Burgess G, Laties AM. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. BMJ. 2012;344:e554.
31. Varma A, Shah KB, Hess ML. Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for Re-evaluation. Congest Heart Fail. 2012;18:229–33.
32. Kanlop N, Shinlapawittayatorn K, Sungnoon R, Chattipakorn S, Lailerd N, Chattipakorn N. Sildenafil citrate on the inducibility of ventricular fibrillation and upper limit of vulnerability in swine. Med Sci Monit. 2008;14:BR205–9.
33. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;1:CD002230.
34. Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60:768–74.
35. Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, et al. Eur J Clin Pharmacol. 2013;70:147–54.